SCHEMBL884369

SCHEMBL884369

O=C(NCCCn1c(C(=O)N2CCNCC2)c(-c2ccccc2)n(C2CCCN(S(=O)(=O)c3ccccc3)C2)c1=O)c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP5 P45974 1/20 0.38
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
NAMPT P43490 1/20 0.36
LMNA P02545 5/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
PKM P14618 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
ALDH1A1 P00352 3/20 0.35
USP2 O75604 1/20 0.35
POLB P06746 1/20 0.35
HTT P42858 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10224854 0.97 USP5 (0.37) USP5KMT2AMEN1NAMPTLMNA
SCHEMBL884393 0.96 USP5 (0.39) USP5KMT2AMEN1NAMPTLMNA
SCHEMBL885536 0.92 PDE10A (0.34) USP5KMT2ASLC6A2SLC6A4NAMPT
SCHEMBL884541 0.90 CYP2C19 (0.36) KMT2AMEN1LMNASMN1; SMN2CYP2C19
SCHEMBL884476 0.89 LMNA (0.35) KMT2AMEN1LMNASMN1; SMN2CYP3A4
SCHEMBL885529 0.88 ALDH1A1 (0.35) USP5NAMPTLMNASMN1; SMN2ALDH1A1
SCHEMBL884768 0.87 SLC6A2 (0.38) SLC6A2SLC6A4SMN1; SMN2ALDH1A1
SCHEMBL884320 0.87 LMNA (0.39) KMT2AMEN1LMNASMN1; SMN2CYP2C19
SCHEMBL884523 0.86 MMP3 (0.35) KMT2AMEN1LMNASMN1; SMN2CYP2C19
SCHEMBL884892 0.84 MMP3 (0.36) KMT2AMEN1LMNASMN1; SMN2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148367-B2 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-03 US claimed
US-20100105665-A1 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-29 US claimed
WO-2008089005-A2 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 WO claimed
US-8148367-B2 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-03 US disclosed
US-20100105665-A1 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-29 US disclosed
WO-2008089005-A2 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 WO disclosed
WO-2008089005-A2 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105665-A1 RENIN INHIBITORS REN, ACE, AGT USP5 1338/4885KMT2A 4058/4885MEN1 1487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.